Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Neurocrine Biosciences (NBIX)

Neurocrine extends Eiry Roberts' employment agreement to December 31, 2026

Neutral Impact 2 of 5 leadership Written later

Neurocrine Biosciences amended the employment agreement with Eiry W. Roberts, M.D., its former Chief Medical Officer, on November 21, 2025. The amendment extends her employment term by 12 months, to December 31, 2026. Sanjay Keswani, M.D. has served as Chief Medical Officer since June 2, 2025, so the change does not alter that role.

Key points

  • Amendment dated November 21, 2025 extends the term of employment by an additional 12 months, expiring December 31, 2026.
  • Sanjay Keswani, M.D. succeeded Dr. Roberts as Chief Medical Officer effective June 2, 2025.
  • Under the prior agreement, Dr. Roberts served as Strategic Advisor through December 31, 2025.
  • Full text of the amendment is filed as Exhibit 10.1.

The filing

CompanyNeurocrine Biosciences (NBIX)
Form8-K, current report
Filed with the SECNov 24, 2025, 4:02 PM ET
Accession number0000914475-25-000186

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 24, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.